Drug intelligence / Profile preview

pri-miR-126

Development stage
Unknown
Modality
MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
Administration
Intravenous
01

Overview

pri-miR-126 is the primary microRNA precursor for miR-126 and miR-126(*). This microRNA pair has been shown to independently suppress the sequential recruitment of mesenchymal stem cells and inflammatory monocytes into the tumor stroma, thereby inhibiting lung metastasis by breast tumor cells in a mouse xenograft model. Its expression is downregulated in cancer cells due to promoter methylation of its host gene Egfl7, and this downregulation correlates with poor metastasis-free survival in breast cancer patients. The mechanism involves direct inhibition of stromal cell-derived factor-1 alpha (SDF-1α) expression and indirect suppression of chemokine (C-C motif) ligand 2 (Ccl2) expression by cancer cells in an SDF-1α-dependent manner.

Other names
miR-126/miR-126(*) precursor
02

Targets

EGFL7HOXA9 (Homeobox protein Hox-A9)IRS1 (Insulin receptor substrate 1)PIK3R2 (PI3K regulatory subunit beta)CXCL12 (C-X-C motif chemokine ligand 12)TOM1 (Target of Myb1 membrane trafficking protein)VCAM1 (Vascular cell adhesion molecule 1)

Beyond the preview

Go deeper on pri-miR-126.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on pri-miR-126.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call